First Wave BioPharma Analyst Ratings
First Wave BioPharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/31/2023 | 251.56% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 01/26/2023 | 251.56% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 12/02/2022 | -21.88% | HC Wainwright & Co. | $8 → $4 | Maintains | Buy |
| 05/26/2022 | 75.78% | Roth Capital | $20 → $9 | Maintains | Buy |
| 12/07/2021 | — | Maxim Group | Downgrades | Buy → Hold |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年1月31日 | 251.56% | HC Wainwright公司 | →$18 | 重申 | →購買 |
| 2023年1月26日 | 251.56% | HC Wainwright公司 | →$18 | 重申 | →購買 |
| 12/02/2022 | -21.88% | HC Wainwright公司 | $8→$4 | 維護 | 買 |
| 2022年05月26日 | 75.78% | 羅斯資本 | $20→$9 | 維護 | 買 |
| 12/07/2021 | - | Maxim集團 | 評級下調 | 購買→Hold |
What is the target price for First Wave BioPharma (FWBI)?
第一波生物製藥(FWBI)的目標價是多少？
The latest price target for First Wave BioPharma (NASDAQ: FWBI) was reported by HC Wainwright & Co. on January 31, 2023. The analyst firm set a price target for $18.00 expecting FWBI to rise to within 12 months (a possible 251.56% upside). 4 analyst firms have reported ratings in the last year.
第一波生物製藥(納斯達克：FWBI)的最新目標價是由HC Wainwright&Co.於2023年1月31日報道的。這家分析公司將目標價定為18美元，預計FWBI將在12個月內升至(可能上漲251.56)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for First Wave BioPharma (FWBI)?
第一波生物製藥(FWBI)的最新分析師評級是多少？
The latest analyst rating for First Wave BioPharma (NASDAQ: FWBI) was provided by HC Wainwright & Co., and First Wave BioPharma reiterated their buy rating.
第一波生物製藥(納斯達克代碼：FWBI)的最新分析師評級由HC Wainwright&Co.提供，第一波生物製藥重申其買入評級。
When is the next analyst rating going to be posted or updated for First Wave BioPharma (FWBI)?
第一波生物製藥(FWBI)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of First Wave BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for First Wave BioPharma was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與第一波生物製藥的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。第一波生物製藥的上一次評級是在2023年1月31日提交的，所以你應該預計下一次評級將在2024年1月31日左右的某個時候提供。
Is the Analyst Rating First Wave BioPharma (FWBI) correct?
分析師對第一波生物製藥(FWBI)的評級正確嗎？
While ratings are subjective and will change, the latest First Wave BioPharma (FWBI) rating was a reiterated with a price target of $0.00 to $18.00. The current price First Wave BioPharma (FWBI) is trading at is $5.12, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的第一波生物製藥(FWBI)評級被重申，目標價在0.00美元至18.00美元之間。First Wave BioPharma(FWBI)目前的交易價格為5.12美元，在分析師的預測範圍內。